HOME >> MEDICINE >> NEWS
UCSF study finds that an osteoporosis prevention drug reduces the risk of breast cancer by 76 percent in postmenopausal women

Researchers at the University of California, San Francisco report that a novel osteoporosis prevention drug, called raloxifene, reduced the risk of invasive breast cancer in postmenopausal women with osteoporosis by 76 percent after forty months of treatment.

The final results of the Multiple Outcomes of Raloxifene Evaluation (MORE) trial are published in the June 16 issue of The Journal of the American Medical Association (JAMA).

"This is an exciting start because women who are concerned about breast cancer now have another alternative for reducing their risk of developing the disease and preventing osteoporosis at the same time," says Steven R. Cummings, MD, UCSF professor of medicine and epidemiology and lead author of the study. "If raloxifene's benefits continue over a longer period of time, treatment with the drug may be a way of substantially reducing a woman's lifetime risk of breast cancer."

The overall 76 percent reduction in the incidence of breast cancer is due to a 90 percent reduction in the risk of estrogen-receptor positive breast cancer (ER+) and 0.88 reduction in the risk of estrogen-receptor negative (ER-) breast cancer among study participants who received raloxifene, Cummings says. ER+ breast cancer is the most common type of breast cancer among older postmenopausal women, accounting for approximately 75 percent of all cases in this population.

ER+ breast cancer tumor cells contain a protein, or receptor, that responds to estrogen and stimulates tissue growth in a woman's breasts, increasing her risk of breast cancer.

During the UCSF-led study, which took place at 180 clinical centers, 7,705 postmenopausal women (mean age 66.5 years) with osteoporosis who were at a low to average risk of developing breast cancer were randomized to receive either 60 milligrams (mg) or 120 mg of raloxifene per day, or a matching placebo. Of these women, 2,572 received 120 mg of raloxifene daily; 2,557 received 60 mg and one placebo tabl
'"/>

Contact: Abby Sinnott
asinnott@pubaff.ucsf.edu
415-885-7277
University of California - San Francisco
16-Jun-1999


Page: 1 2 3

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. UMaine study looks at infants and chronic nighttime crying
3. Chronic pain treatments more effective when taken together, new study shows
4. UNC study: Most N.C. family practitioners engage in unrecognized community service
5. New study in Nature demonstrates protection against cell death during heart attack
6. UCSF study offers insight into human circadian rhythms
7. International breast cancer prevention study launches in the United States and Canada
8. UW study shows blacks and Latinos are more satisfied with physicians of the same race
9. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
10. Advertising by academic medical centers may risk eroding public trust, says study
11. Fat may promote inflammation, new study suggests

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 02, 2020 , ... The Coronavirus ... for non-emergency work. In conjunction with the American Dental Association and Centers for ... in mid-May. , Due to safety concerns, the announcement sparked hesitancy among ...
(Date:7/1/2020)... ... July 01, 2020 , ... The ... Associate Professor of Medicine at the University of Massachusetts Medical School- Baystate and ... have joined the SIDM Board of Directors. Dr. Salvador and Ms. Gaffey’s service ...
(Date:6/28/2020)... ... ... PathAI, a global provider of artificial intelligence (AI)-powered technology for use in ... PD-L1 expression to assess response in patients treated with Bristol Myers Squibb’s PD-1 inhibitor, ... Research (AACR) Annual Meeting. AACR was held June 22 to June 24. , The ...
(Date:6/28/2020)... ... June 27, 2020 , ... The FSHD ... full-day educational conference in the organization’s history. The online conference takes the place ... which was cancelled this year due to COVID-19. Nearly 300 individuals and families ...
(Date:6/24/2020)... BEACH, Calif. (PRWEB) , ... June 24, 2020 , ... ... it has launched a new website at http://www.evolvednaturals.com The newly launched website ... of broad-spectrum CBD oils , and a comprehensive line of skincare & ...
Breaking Medicine News(10 mins):
(Date:7/7/2020)... ... July 07, 2020 , ... CHESS ... Psych Hub, the leading comprehensive platform for online education on mental health, substance ... resources to Substance Use Disorder (SUD) patients throughout each step of the treatment ...
(Date:7/7/2020)... ... 07, 2020 , ... SupplyPro announces a Contact Tracing function available on its ... one of us. SupplyPro is dedicated to supporting the worldwide response to COVID-19. Recent ... - a powerful tool in the fight against the spread of COVID-19. , ...
(Date:7/2/2020)... , ... July 02, 2020 , ... AllenComm, the leader ... projects and four Omni Awards for visually compelling compliance training , onboarding ... to meet and exceed client and industry expectations as a digital transformation partner for ...
Breaking Medicine Technology:
Cached News: